CSF1R and neoplasm: While CSF1R inhibitors and CD40 agonists potently reduce tumor growth in mice, the combined use of Emactuzumab (anti-CSF1R monoclonal antibody) with Selicrelumab (agonistic CD40 monoclonal antibody) in patients with metastatic PDAC has not translated into objective clinical responses (NCT02760797) [188].